{"id":14986,"date":"2018-10-02T13:30:26","date_gmt":"2018-10-02T04:30:26","guid":{"rendered":"http:\/\/mus.brc.riken.jp\/ja\/?page_id=14986"},"modified":"2018-10-04T09:26:33","modified_gmt":"2018-10-04T00:26:33","slug":"info20181002","status":"publish","type":"page","link":"http:\/\/mus.brc.riken.jp\/ja\/info20181002","title":{"rendered":"\u30de\u30a6\u30b9\u306b\u304a\u3051\u308bPD-1\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u6a5f\u69cb\u3092\u89e3\u660e\u3059\u308b\u305f\u3081\u306e\u7814\u7a76\u30c4\u30fc\u30eb"},"content":{"rendered":"

<\u672c\u5eb6\u4f51\u5148\u751f\u30ce\u30fc\u30d9\u30eb\u8cde\u53d7\u8cde\u304a\u3081\u3067\u3068\u3046\u3054\u3056\u3044\u307e\u3059\uff01><\/a>
\n

\n2018\u5e74\u306e\u30ce\u30fc\u30d9\u30eb\u533b\u5b66\u30fb\u751f\u7406\u5b66\u8cde\u306f\u300c\u514d\u75ab\u6291\u5236\u306e\u963b\u5bb3\u306b\u3088\u308b\u304c\u3093\u6cbb\u7642\u6cd5\u306e\u767a\u898b\u300d\u3067\u3001\u672c\u5eb6\u4f51\u7279\u5225\u6559\u6388\uff08\u4eac\u90fd\u5927\u5b66\uff09\u304c\u30b8\u30a7\u30fc\u30e0\u30ba\u30fb\u30a2\u30ea\u30bd\u30f3\u6559\u6388\uff08\u7c73\u30c6\u30ad\u30b5\u30b9\u5927\u5b66\uff09\u3068\u5171\u540c\u53d7\u8cde\u3055\u308c\u307e\u3057\u305f[1]\u3002\u672c\u5eb6\u7279\u5225\u6559\u6388\u3089\u306fT\u7d30\u80de\u306e\u8868\u9762\u306b\u767a\u73fe\u3059\u308b\u5206\u5b50\u3067\u3042\u308bPD-1\u3092\u767a\u898b\u3057\u3001\u751f\u4f53\u5185\u306b\u304a\u3044\u3066\u514d\u75ab\u53cd\u5fdc\u3092\u8ca0\u306b\u5236\u5fa1\u3059\u308b\u30d6\u30ec\u30fc\u30ad\u306e\u5f79\u5272\u3092\u679c\u305f\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u660e\u3089\u304b\u306b\u3057\u307e\u3057\u305f[2-5]\u3002\u3055\u3089\u306b\u3001PD-1\u30b7\u30b0\u30ca\u30eb\u3092\u30d6\u30ed\u30c3\u30af\u3059\u308b\u3053\u3068\u3067\u514d\u75ab\u7cfb\u304c\u304c\u3093\u3092\u653b\u6483\u3067\u304d\u308b\u53ef\u80fd\u6027\u304c\u793a\u5506\u3055\u308c\u305f\u3053\u3068\u304b\u3089\u3001PD-1\u306b\u5bfe\u3059\u308b\u6297\u4f53\u3092\u7528\u3044\u305f\u304c\u3093\u306e\u514d\u75ab\u6cbb\u7642\u6cd5\u3092\u4e16\u754c\u306b\u5148\u99c6\u3051\u3066\u63d0\u5531\u3055\u308c\u307e\u3057\u305f[6]\u3002\u73fe\u5728\u3067\u306f\u3001\u3053\u306e\u6cbb\u7642\u6cd5\u306f\u6700\u3082\u52b9\u679c\u7684\u306a\u304c\u3093\u6cbb\u7642\u6cd5\u306e\u3072\u3068\u3064\u3068\u3057\u3066\u4e16\u754c\u4e2d\u306e\u81e8\u5e8a\u306e\u5834\u3067\u7528\u3044\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u7406\u7814BRC\u30fb\u5b9f\u9a13\u52d5\u7269\u958b\u767a\u5ba4\u3067\u306f\u3001PD-1\u306e\u5f79\u5272\u3092\u660e\u3089\u304b\u306b\u3059\u308b\u30c4\u30fc\u30eb\u3068\u3057\u3066\u6709\u7528\u306a\u30de\u30a6\u30b9\u7cfb\u7d71\u3092\u306f\u3058\u3081\u3001\u514d\u75ab\u6a5f\u69cb\u306e\u89e3\u660e\u306b\u6709\u7528\u306a\u591a\u6570\u306e\u7cfb\u7d71\u3092\u672c\u5eb6\u7279\u5225\u6559\u6388\u304b\u3089\u5bc4\u8a17\u3044\u305f\u3060\u3044\u3066\u304a\u308a\u3001\u3053\u308c\u307e\u3067\u306b\u4e16\u754c\u306e200\u6a5f\u95a2\u4ee5\u4e0a\u306b\u63d0\u4f9b\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u7686\u69d8\u306e\u3054\u5229\u7528\u3092\u304a\u5f85\u3061\u3044\u305f\u3057\u3066\u304a\u308a\u307e\u3059\u3002<\/p>\n

\u7cfb\u7d71\u306e\u30ea\u30b9\u30c8<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t
RBRC No.<\/th>Strain name<\/th>\n<\/tr>\n<\/thead>\n
RBRC00903<\/a><\/td>C.129S2-Pdcd1<tm1Hon>\/HonRbrc (N10)<\/td>\n<\/tr>\n
RBRC00904<\/a><\/td>C.129S2-Pdcd1<tm1Hon>\/HonRbrc (N12)<\/td>\n<\/tr>\n
RBRC02142<\/a><\/td>B6.129S2-Pdcd1<tm1Hon>\/HonRbrc<\/td>\n<\/tr>\n
RBRC02361<\/a><\/td>NOD.129S2(B6)-Pdcd1<tm1Hon><\/td>\n<\/tr>\n
RBRC02363<\/a><\/td>C.129S2-Pdcd1<tm1Hon>(N20)<\/td>\n<\/tr>\n
RBRC02364<\/a><\/td>MRL.129S2(B6)-Pdcd1<tm1Hon><\/td>\n<\/tr>\n
RBRC02365<\/a><\/td>C57BL\/6-Tg(Actb-Pdcd1)BHon<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/p>\n



\n\u6587\u732e<\/strong>
\n[1]\tThe 2018 Nobel Prize in Physiology or Medicine
\nhttps:\/\/www.nobelprize.org\/prizes\/medicine\/2018\/<\/a>
\n[2]\tIshida Y, Agata Y, Shibahara K, Honjo T. (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11):3887-95.
\n[3]\tNishimura H, Nose M, Hiai H, Minato N, Honjo T. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141-51.
\n[4]\tFreeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192(7):1027-34.
\n[5]\tNishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502):319-22.
\n[6]\tIwai Y, Terawaki S, Honjo T. (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 17(2):133-44.
\n

\n\u95a2\u9023\u8a18\u4e8b\uff08\u4eca\u6708\u306e\u30de\u30a6\u30b9\uff09<\/strong><\/p>\n